Market Cap 16.05M
Revenue (ttm) 0.00
Net Income (ttm) -96.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,700
Avg Vol 31,561
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 67%
Beta 3.01
Analysts Hold
Price Target $4.00

Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 620 8501
Address:
18706 North Creek Parkway, Suite 104, Bothell, United States
Whales22
Whales22 Oct. 24 at 8:43 PM
How much volume do you think it takes to gap CMCT up? CMCT has not even 700K shares float and recent news. Hoping for a 100% run on CMCT $ECDA $ATHA $SQNS $VCIG <
0 · Reply
Whales22
Whales22 Oct. 23 at 7:55 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ECDA $ATHA $SQNS $VCIG Watchlist,
0 · Reply
makedatbread88
makedatbread88 Oct. 21 at 6:08 PM
$ATHA somethings up with this one Reverse split back in September 3M small float Double normal volume someone’s loading
0 · Reply
Stekli27
Stekli27 Oct. 18 at 10:21 PM
$NRSN People forget that biotech breakouts never happen when everyone expects them. Look at $ATHA, $ANVS, $AMLX, all were completely dead for weeks before exploding 300 to 600 percent. Same setup here: AI based patient stratification, strong Phase 2 data in ALS and Alzheimer’s, and a ready to go Phase 3 program waiting for funding or a deal. No hype, no noise, no attention, exactly how it looked before the big runs in 2022 to 2024. The difference now is that NRSN targets two major diseases and combines it with AI driven biomarker precision. The market doesn’t understand it yet, but when the announcement comes, it won’t wait. Quiet periods like this are not weakness. They are compression before the spring snaps.
2 · Reply
TwongStocks
TwongStocks Oct. 17 at 8:05 PM
One month post-RS recap. $ATHA 1:10 RS Sep 18, closed $3.83. Post-rs high $4.59 Oct 6. Fell to post-rs low $3.60 on Oct 16. Best swing was Sep 19-Oct 6. Low of $3.66 Sep 19 to $4.59 on Oct 6. Swing of 25.4% from Sep 19-Oct 6. Today closed $3.62, down 5.48% from RS close. $ECDA 1:40 RS Sep 18, closed $4.32. Post-rs high $5.00 Oct 8. Fell to post-rs low $2.26 today. Best swing was Sep 22-Oct 8. Low of $3.42 Sep 22 to $5.00 on Oct 8. Swing of 46.2% from Sep 22-Oct 6. Today closed $2.47, down 42.82% from RS close.
0 · Reply
11thestate
11thestate Oct. 16 at 12:19 PM
$ATHA is now accepting claims for a $10M settlement it is paying to investors over claims that it misled the market about research integrity and data manipulation by its former CEO. Even if you missed the deadline, if you bought $ATHA between September 17, 2020, and June 17, 2021, you still can file for payment here: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=10162025_1
0 · Reply
Jtlo
Jtlo Oct. 12 at 3:05 PM
$OVID which one should I place some money in $GANX $COYA $ATHA
4 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:17 PM
Keep a close watch on CMCT! $BIAF $ECDA $ATHA $SQNS +
0 · Reply
AZOZ
AZOZ Oct. 9 at 5:22 PM
$ATHA Uptrend 👀
0 · Reply
11thestate
11thestate Oct. 8 at 2:21 PM
$ATHA is accepting claims for a $10M settlement to resolve allegations it misled investors about research integrity after its former CEO, Dr. Leen Kawas, was accused of altering images in scientific papers to inflate the company’s credibility and stock price. Even if you missed the deadline, if you bought $ATHA between September 17, 2020, and June 17, 2021, you still can file for payment here: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=10082025_1
0 · Reply
Latest News on ATHA
Athira Pharma Announces Reverse Stock Split

Sep 11, 2025, 9:00 AM EDT - 6 weeks ago

Athira Pharma Announces Reverse Stock Split


Athira Pharma to Participate in Upcoming June Conferences

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences


Athira Pharma to Participate in Upcoming May Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Conferences


Athira Pharma Provides 2023 Pipeline Outlook

Jan 5, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Provides 2023 Pipeline Outlook


Whales22
Whales22 Oct. 24 at 8:43 PM
How much volume do you think it takes to gap CMCT up? CMCT has not even 700K shares float and recent news. Hoping for a 100% run on CMCT $ECDA $ATHA $SQNS $VCIG <
0 · Reply
Whales22
Whales22 Oct. 23 at 7:55 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ECDA $ATHA $SQNS $VCIG Watchlist,
0 · Reply
makedatbread88
makedatbread88 Oct. 21 at 6:08 PM
$ATHA somethings up with this one Reverse split back in September 3M small float Double normal volume someone’s loading
0 · Reply
Stekli27
Stekli27 Oct. 18 at 10:21 PM
$NRSN People forget that biotech breakouts never happen when everyone expects them. Look at $ATHA, $ANVS, $AMLX, all were completely dead for weeks before exploding 300 to 600 percent. Same setup here: AI based patient stratification, strong Phase 2 data in ALS and Alzheimer’s, and a ready to go Phase 3 program waiting for funding or a deal. No hype, no noise, no attention, exactly how it looked before the big runs in 2022 to 2024. The difference now is that NRSN targets two major diseases and combines it with AI driven biomarker precision. The market doesn’t understand it yet, but when the announcement comes, it won’t wait. Quiet periods like this are not weakness. They are compression before the spring snaps.
2 · Reply
TwongStocks
TwongStocks Oct. 17 at 8:05 PM
One month post-RS recap. $ATHA 1:10 RS Sep 18, closed $3.83. Post-rs high $4.59 Oct 6. Fell to post-rs low $3.60 on Oct 16. Best swing was Sep 19-Oct 6. Low of $3.66 Sep 19 to $4.59 on Oct 6. Swing of 25.4% from Sep 19-Oct 6. Today closed $3.62, down 5.48% from RS close. $ECDA 1:40 RS Sep 18, closed $4.32. Post-rs high $5.00 Oct 8. Fell to post-rs low $2.26 today. Best swing was Sep 22-Oct 8. Low of $3.42 Sep 22 to $5.00 on Oct 8. Swing of 46.2% from Sep 22-Oct 6. Today closed $2.47, down 42.82% from RS close.
0 · Reply
11thestate
11thestate Oct. 16 at 12:19 PM
$ATHA is now accepting claims for a $10M settlement it is paying to investors over claims that it misled the market about research integrity and data manipulation by its former CEO. Even if you missed the deadline, if you bought $ATHA between September 17, 2020, and June 17, 2021, you still can file for payment here: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=10162025_1
0 · Reply
Jtlo
Jtlo Oct. 12 at 3:05 PM
$OVID which one should I place some money in $GANX $COYA $ATHA
4 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:17 PM
Keep a close watch on CMCT! $BIAF $ECDA $ATHA $SQNS +
0 · Reply
AZOZ
AZOZ Oct. 9 at 5:22 PM
$ATHA Uptrend 👀
0 · Reply
11thestate
11thestate Oct. 8 at 2:21 PM
$ATHA is accepting claims for a $10M settlement to resolve allegations it misled investors about research integrity after its former CEO, Dr. Leen Kawas, was accused of altering images in scientific papers to inflate the company’s credibility and stock price. Even if you missed the deadline, if you bought $ATHA between September 17, 2020, and June 17, 2021, you still can file for payment here: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=10082025_1
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 2 at 11:46 PM
0 · Reply
DARKP00L
DARKP00L Sep. 23 at 8:36 PM
$ATHA 16:00 on Sep. 23 2025 Athira Pharma Has Been Granted A U.S. Patent "Methods of treating neurodegenerative disease (including dementia, Alzheimer's disease, and Parkinson's disease) with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues". https://t.co/NSHLVnfwcm. #tradeideas
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 23 at 7:57 PM
$ATHA patent headline into the close here.
0 · Reply
PatentGrants
PatentGrants Sep. 23 at 7:57 PM
$ATHA Athira Pharma has been granted a US patent "Methods of treating neurodegenerative disease (including dementia, Alzheimer's disease, and Parkinson's disease) with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues". https://ppubs.uspto.gov/pubwebapp/external.html?q=(12421276).pn.
0 · Reply
11thestate
11thestate Sep. 22 at 10:44 AM
$ATHA is accepting claims for a $10M settlement to resolve allegations it misled investors about research integrity, including claims that its former CEO altered images in scientific papers to inflate stock credibility. Even if you missed the deadline, if you bought $ATHA between September 17, 2020, and June 17, 2021, you still can file for payment here: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=09222025_1
0 · Reply
TwongStocks
TwongStocks Sep. 18 at 8:13 PM
Today's reverse split results. Both closed green: $ATHA 1 for 10 Previous close $0.378, $3.78 split-adjusted Intraday high $4.05 Today's close $3.83 🟢Up 1.32% $ECDA 1 for 40 Previous close $0.0979, $3.916 split-adjusted Intraday high $4.76 Today's close $4.32 🟢Up 10.32%
0 · Reply
TwongStocks
TwongStocks Sep. 18 at 11:37 AM
$ATHA $ECDA Both with reverse splits today. Trading will resume at 9:00a ET with the RS in effect. RS details in the quoted post.
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Sep. 18 at 7:29 AM
$ATHA ** Athira Pharma (ATHA) is undergoing a reverse stock split today, September 18, 2025. The split is at a 1-for-10 ratio. Previous Shares Outstanding: ~39.44 million ​Reverse Split Ratio: 1-for-10 ​New Estimated Shares Outstanding: ~3.94 million.
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Sep. 18 at 2:36 AM
🌞🌞 watchlist part 2 ✅️ $NFE mid 2.50 support, if above 3, have potential to 3.40/.50 ✅️ $ECDA 1/40 reverse split, new price ~ 4 ✅️ $ATHA 1/10 reverse split, new price ~ 3.80 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if below current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $TBH $OTRK still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
TwongStocks
TwongStocks Sep. 17 at 8:54 PM
I am aware of two NASDAQ reverse splits on Thursday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Thursday morning. $ATHA 1 for 10. Will reduce outstanding shares from approx 39.44m to approx 3.94m. $ECDA 1 for 40. Will reduce outstanding shares from approx 59.09m to approx 1.48m.
0 · Reply
TwongStocks
TwongStocks Sep. 16 at 8:11 PM
$ATHA NASDAQ Equity Corporate Actions Alert # 2025 - 509 Information Regarding the Reverse Stock Split and CUSIP Number Change for Athira Pharma, Inc. (ATHA) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-509 Athira Pharma, Inc. (ATHA) will effect a one-for-ten (1-10) reverse split of its Common Stock. The reverse stock split will become effective on Thursday, September 18, 2025. In conjunction with the reverse split, the CUSIP number will change to 04746L203.
0 · Reply
11thestate
11thestate Sep. 9 at 1:42 PM
Losses on $ATHA? Time to take action. See what’s happening: https://11th.com/cases/athira-ipo-spo-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=09092025_1 #ATHA
0 · Reply